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The immunohistochemical determination of HER-2 to identify patients with advanced breast cancer candidates for Trastuzumab
treatment proved neither accurate nor fully reliable, possibly because none of the current reagents detects the specific antigenic site
target of Trastuzumab. To circumvent this problem, we conjugated the NH2 groups of Trastuzumab with biotin, and the compound
obtained, designated BiotHER, was added directly to tissue sections. Biotin-labelling was revealed with horseradish peroxidase-
conjugated streptavidin. Specificity and sensitivity of BiotHER immunostaining with respect to HER-2 amplification were tested on 164
breast carcinoma samples. BiotHER staining was detected on the tumour cell membrane of 12% of all specimens and in 49%
specimens with gene amplification, while absent in nonamplified tumours. Predictivity of BiotHER status with respect to the clinical
outcome was analysed in 54 patients with HER-2 amplified advanced breast cancer treated with Trastuzumab plus chemotherapy.
BiotHER staining, detected in 50% of tumours with HER-2 amplification, was an independent predictor of clinical outcome. In fact,
BiotHER positivity was independently associated with increased likelihood of tumour response and reduced risk of tumour
progression and death. Biotinylated Trastuzumab can thus be used for immunohistochemical detection of HER-2 overexpression in
breast cancer, and has the potential to identify patients likely to benefit from Trastuzumab treatment.
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Overexpression of the HER-2 transmembrane receptor is detected
in 25–30% of human breast cancers (Slamon et al, 1987, 1989) and
is a direct result of gene amplification (Pauletti et al, 1996) in
approximately 90–95% of cases. Demonstration of HER-2 antigen
overexpression in breast cancer constitutes the rationale for
treatment with Trastuzumab (Baselga et al, 1998). Trastuzumab
consists of the antigen-binding fragment (Fab) of the murine mAb
4D5, directed against the extracellular domain (ECD) of HER-2,
spliced to the Fc fragment of human IgG (Baselga et al, 1998). The
4D5 mAb was humanised to minimise the immunogenicity
associated with the murine counterpart and to maximise its
potential to recruit endogenous immune effector cells (Tokuda
et al, 1996; Baselga et al, 1998). As a single agent, Trastuzumab
produced a response rate of 15–26% in women with HER-2-
overexpressing advanced breast cancer (Cobleigh et al, 1999; Vogel
et al, 2002). Combined with chemotherapy, Trastuzumab has
resulted in increased response rate and survival (Slamon et al,
2001, Montemurro et al, 2004b) in this clinical setting of patients.
The clinical response to Trastuzumab can be predicted by
immunohistochemical (IHC) determination of HER-2 receptor
expression in tumour cell membranes (Slamon et al, 2001;
Montemurro et al, 2004b). However, establishing the presence of
HER-2 gene amplification by fluorescence in situ hybridisation
(FISH) seems to be a more accurate, reliable and cost-effective
method for selecting patients eligible for Trastuzumab therapy
(Elkin et al, 2004) than IHC, perhaps because none of the available
IHC procedures detect the Trastuzumab epitope. In fact, the
Trastuzumab-binding site has been mapped to the C-terminal
portion of domain IV in the juxtamembrane region of the ECD
(Cho et al, 2003). On the contrary, other commercial products used
for HER-2 receptor testing do not recognise the same epitope as
Trastuzumab. Specifically, Herceptest, and mAb CB11 recognise
the intracellular domain of HER-2 (Corbett et al, 1990; Ceccarelli
et al, 1999). On the other hand, mAb TAB250 recognises the ECD
but the epitope is unknown (Ceccarelli et al, 1999) (Figure 1).
Previously, we demonstrated that by combining the score values
obtained by CB11 and TAB250 mAbs in a double scoring system,i t
was possible to predict the gene status in 58% of cases of breast
cancer (Sapino et al, 2003), thus proving the interest for IHC
detection of the ECD.
However, to predict Trastuzumab activity, it is essential to verify
the availability of the Trastuzumab target epitope, especially since
several studies have demonstrated the occurrence of tumours
expressing variants of the HER-2 protein (Christianson et al, 1998;
Kwong and Hung, 1998; Molina et al, 2001, 2002). Many cell
surface transmembrane proteins, including growth factor recep-
tors, can be released from the cell surface by a general shedding
system activated by several independent mechanisms. The ECD of
the HER-2 may be cleaved and shed from the receptor and can be
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cancer as a protein of approximately 105kDa (Hayes et al, 2001).
Such shedding process is actively regulated by proteolytic
processes. In addition, in in vitro experiments using Trastuzumab
as antibody for immunoprecipitation analysis, it has been shown
that the soluble ECD in the medium maintains the Trastuzumab
epitope, which is lost in the cell lysates (Codony-Servat et al, 1999).
This shedding generates an NH2-terminally truncated HER-2
product of Mr 95000 demonstrated in cell lines and in breast
cancer tissues (Christianson et al, 1998; Molina et al, 2001, 2002).
In these circumstances, patients are still selected as candidates for
Trastuzumab therapy on the basis of gene amplification analyses
and staining procedures that recognise the intracytoplasmic
portion, but treatment is doomed to fail because of the lack of
the Trastuzumab epitope.
A straightforward approach would be to use Trastuzumab as the
primary Ab in IHC. However, technical reasons impede this
because antigen detection using a primary Ab of the same species
as the target tissue is complicated by high background staining.
The present study demonstrates that, following modification,
Trastuzumab can be used reliably to detect overexpression of its
antigen by IHC. In a series of cancer samples of different organs,
this novel IHC test was compared to commercial antibodies in
detecting HER-2 overexpression and with in situ hybridisation
procedures that reveal gene amplification. Finally, in a series of
patients with HER-2-amplified advanced breast cancer treated with
Trastuzumab plus chemotherapy, we retrospectively studied the
predictivity of BiotHER status with respect to clinical outcome.
MATERIALS AND METHODS
Rationale for the procedure and preparation of reagents
The modification of Trastuzumab consisted in conjugating the
mAb to biotin which binds NH2 groups of the mAb. Trastuzumab,
commercially available as Herceptin
s (Roche, Hertfordshire, UK),
is distributed in vials for use in breast cancer treatment. One
milligram of Trastuzumab from a vial of Herceptin
s was diluted in
saline solution (1mgml
 1 concentration) and dialysed overnight
in 0.1 M Na2CO3, pH 8.5. To 1ml solution, 0.12ml of e-
caproylamido-biotin-n-hydroxy-succinimide ester (Biospa, Mila-
no, Italia) was added. The preparation was mixed by gentle
agitation for 4h at room temperature (RT) and dialysed in
phosphate-buffered saline (PBS). The product, designated Bi-
otHER stock solution, was stored frozen at  801Ci n2 0ml aliquots
and sublimated. The lyophilized mAb was stored in vials.
Immunohistochemical methods for BiotHER
immunostaining
To set up the IHC procedure for BiotHER, we used cell pellet of
BT474 breast cancer cells (American Type Culture Collection,
Manassas, VA, USA) and a tissue array of 10 breast cancers with
different HER-2 gene status (five amplified and five nonamplified
tumours). Cells were maintained at 371C and 5% CO2 in
Dulbecco’s modified Eagle’s medium 13 (DMEM) (Sigma-Aldrich)
containing 10% fetal calf serum (Biochrom-Berlin). Confluent cells
were scraped and centrifuged. Cell pellets were fixed in 10%
neutral-buffered formalin, then embedded in paraffin. Deparaffi-
nised tissue sections were brought to PBS, then covered with 25ml
BiotHER, final dilution 1:2000 in PBS (protein con-
centration¼0.5mgml
 1). Sections were incubated for 1h at RT,
washed twice for 5min in PBS. Biotin label of BiotHER was then
revealed incubating with horseradish peroxidase (HRP)-conju-
gated streptavidin diluted 1:50 (BioGenex, San Ramon, CA, USA)
for 13min at RT. Since preliminary tests showed that BiotHER
reactivity was not improved by antigen retrieval (MW or
proteinase digestion), we eventually avoided this procedure.
Sections were then washed in PBS and the reaction was routinely
developed in a solution of 30-3-diaminobenzidine (DAB) and H2O2
for 5min. Nuclei were counterstained with Mayer Haemalum for
30s. Dehydration in alcohols, clarification in xylol and mounting
in Entellan followed. Positivity corresponded to membrane
staining. Evaluation was performed with the four-tiered
scoring system (see below). For quality control analysis, conjuga-
tion of biotin to Trastuzumab was performed every week for a total
of five biotinylation processes and the obtained BiotHER
compound was tested at each time point by IHC in the control
tissues. To test preservation of immunoreactivity, lyophilised
BiotHER stock was tested every 2 weeks by IHC procedures on the
control tissue array.
To correlate gene amplification and BiotHER immunoreactivity
with Herceptest and TAB250 immunoreactivity, we tested these
antibodies on tissue arrays prepared from tumours of different
organs (164 primary breast carcinomas, 28 colon, 28 lung, 28
ovarian and 26 prostate cancers). All tissues were formalin fixed
and paraffin embedded. In 24 breast carcinomas, immunohisto-
chemistry using 4D5 mAb was also performed.
Herceptest (Dako Corp., Carpenteria, CA, USA) was utilised
according to the manufacturer’s instructions. TAB250 mAb
(Zymed, San Francisco, CA, USA) was used as previously reported
(Sapino et al, 2003). After blocking nonspecific binding sites
(Histostain Plus kit, Zymed), sections were incubated for 30min at
371C with TAB250 diluted 1:40, then incubated for 20min with
secondary biotinylated anti-mouse Ig antibody (1:50, BioGenex),
followed by HRP-conjugated streptavidin (1:50, StrAviGen Multi-
Link Kit, BioGenex) for additional 20min at RT. Sections were also
stained using the 4D5 mAb (not commercially available and kindly
supplied by Dr PG Natali, Regina Elena Cancer Institute, Rome,
Italy). For IHC, mAb 4D5 was diluted 1:1000 following the
methods used for TAB250 mAb. As with BiotHER, we did not
observe any advantages for reactivity of 4D5 by antigen retrieval
procedures. The four-tiered scoring system (0, 1þ,2þ and 3þ
score values) suggested by the manufacturers to evaluate the
results of Herceptest and TAB250 in breast cancer tissue was
applied to these Abs and also to BiotHER and 4D5 results. HER-2
protein expression was defined as negative (scores 0 and 1þ)o r
positive (scores 2þ and 3þ). This analysis was performed
double-blindly.
4D5 mAb 
(Herceptin) 
epitope in domain IV in a 
cystein-rich region closed 
to transmembrane 
Herceptest polyclonal     → ?
CB-11 mAb                   → ?
TAB250 mAb         → ?
Transmembrane domain
Figure 1 Site of binding of different antibodies used in the IHC detection
of HER-2 overexpression in breast cancer. The exact epitope recognised
by some reagents is presently unknown.
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sAll cases were then studied with Chromogenic Insitu Hybridiza-
tion (CISH) and/or FISH to assess HER-2 gene amplification.
BiotHER sensitivity and specificity were calculated using the
known HER-2 gene status of the tumour as the gold standard.
Fluorescence in situ hybridisation or CISH procedures
PathVysion HER-2/neu probe kit (Vysis Inc., Downers Grove, IL,
USA) was used for FISH analysis. In brief, sections were baked
overnight at 561C, and invasive carcinoma components were
selected based on haematoxylin and eosin-stained sections,
deparaffinised in CitriSolv, dehydrated in 100% ethanol and air-
dried. Slides were then treated with proteases for 45–60min,
denatured and hybridised overnight at 371C with the probes (HER-
2/neu/CEP17 SG probe 35–171060, Vysis Inc., Downers Grove, IL,
USA). Slides were washed with posthybridisation buffer at 721C,
counterstained with 40,60-diamidino-2-phenylindole (DAPI),
mounted and stored in the dark prior to signal enumeration.
Slides were first scanned at low power with a DAPI filter to identify
areas of optimal tissue digestion and nonoverlapping nuclei. Cases
were scored as amplified when the ratio of HER-2/chromosome 17
signals were X2.0. This analysis was performed double-blindly.
For CISH analysis, the sections were deparaffinised in xylene and
99% alcohol, air-dried for 10min and then heated above 981C for
15min in CISH Tissue Heat Pretreatment. The sections were then
rinsed in dH2O and digested with pepsin for 10min. Afterwards,
sections were washed in dH2O, dehydrated with graded alcohol,
and air-dried. The ready-to-use digoxigenin-labelled HER-2/neu
probe (consisting of two contig BAC clones; Zymed Lab) was
applied onto slides, which were covered by 14 14mm coverslips
(10ml probe mixture/slide). The slides were denatured on a hot
plate (94–951C) for 5min, and the hybridisation was performed
overnight at 371C. After hybridisation, the slides were washed with
0.5 SCC prewarmed at 751C for 5min, followed by three washes
in dH2O. The HER-2/neu probe was detected with sequential
incubations with mouse anti-digoxigenin antibody for 45min
followed by incubation with polymerised HRP-anti-mouse anti-
body for another 45min and diaminobenzidine according to the
manufacturer’s instructions (Zymed). Tissue sections were lightly
counterstained with methyl green.
Amplified cases had both low level amplification (showing 6–10
signals per nucleus in 450% of cancer cells, or a small gene
copy cluster), and high level HER-2 gene amplification (showing a
large gene copy cluster in 450% of carcinoma cells or 410
separate gene copies), as defined in the original report (Sapino
et al, 2003).
Patients
To evaluate the impact of BiotHER immunostaining on Trastuzu-
mab response, IHC analysis with BiotHER was performed in
specimens from 54 women with HER-2 amplified advanced
breast cancer. These cases were selected because: (i) they had
been treated with Trastuzumab combined with chemotherapy, (ii)
their tumour blocks were available for retesting and (iii) their
follow-up data was available. All 54 cases were re-evaluated with
BiotHER and FISH. The patients had started treatment between
September 1999 and July 2004. Immunohistochemical positivity
was originally scored 3þ in 45 patients and 2þ in nine patients.
For seven of these 2þ tumours, a FISH test showing HER-2
amplification had been obtained before initiating therapy with
Trastuzumab.
Treatment In all 54 patients, Trastuzumab was administered
using the weekly schedule (4mgkg
 1 loading dose, followed by
2mgkg
 1 weekly). Trastuzumab was combined with docetaxel
75mgm
 2 every 3 weeks in 42 patients, including 34 who were
treated in a phase II multi-institutional trial (Montemurro et al,
2004a), and vinorelbine 30mgm
 2 on days 1 and 8 every 3 weeks
for the remaining 12 patients. For both docetaxel and vinorelbine,
the treatment was planned to be given for a maximum of six cycles
with concomitant weekly Trastuzumab. Patients showing tumour
response or stabilisation upon the completion of chemotherapy
continued weekly Trastuzumab until disease progression or
unacceptable toxicity.
Tumour response was classified according to WHO criteria (CR:
complete remission, PR: partial remission, SD: stable disease, PD:
progressive disease) (Miller et al, 1981). Response rate (RR, CR
plus PR) is reported together with its 95% confidence interval
(95% CI), as calculated by the Wilson’s method (Wilson, 1927).
The Kaplan–Meier product limit method was used to determine:
(1) time to progression (TTP), which was calculated from the date
of the first dose of docetaxel and Trastuzumab and the date of the
first documented tumour progression or death in the absence of
tumour progression; (2) overall survival (OS), which was
calculated from the date of the first dose of Trastuzumab to the
date of documented death of the patients. Alive patients were
censored at the date of most recent follow-up visit.
Statistical analysis The concordance among IHC assay methods
was studied by the K statistics. The difference in RR between
subgroups of patients was analysed by Fisher’s Exact Test.
Differences in TTP and OS between different subgroups of patients
were analysed by the log-rank test. The effect of BiotHER positivity
on RR was studied by logistic regression analysis including
potential covariates. Results are reported as odds ratio (OR) with
95% CI. Similarly, the effect of BiotHER positivity on TTP and OS
was studied in a Cox’s Proportional Hazards model including
potential covariates. Results are reported as hazard ratio (HR) with
95% CI. The P-values were calculated by means of the Wald
statistic and considered significant if p0.05. The statistical
analysis was performed using the SPSS-PC software, version 11.5
(SPSS, Chicago, IL, USA).
RESULTS
Definition of HER-2 expression by immunohistochemistry
HER-2 protein receptor overexpression was located on membranes
of BT474 breast cancer cells with all the mAbs tested, that is,
Herceptest, TAB250 and BiotHER (Figure 2A). The quality
control analysis demonstrated that conjugation process with biotin
had a reproducibility of 100%, while the immunoreactivity was
lost after 3 months from biotinylation. Staining with BiotHER
was invariably detected on the cell membrane, while cytoplasmic
staining (Figure 2B) or staining of stroma and of normal
residual epithelial cells was never observed (Figure 2C, D).
Fluorescence in situ hybridisation analysis of the 164 specimens
from primary breast cancers showed HER-2 gene amplification in
42 cases (26%). The only 21 specimens that stained positively
by BiotHER had HER-2 gene amplification (Figure 2E, F arrows).
Concordance of BiotHER with Herceptest and TAB250
are summarised in Table 1a and b. MAb 4D5 was studied in 24
of the 164 breast carcinomas. Of 14 cases with HER-2 amplifica-
tion, nine were positive with both BiotHER and 4D5, whereas two
were negative with both tests, and in three cases 4D5 alone was
positive. The 10 nonamplified cases studied were negative for both
4D5 and BiotHER staining (K for overall concordance¼0.75,
Po0.01).
None of the other specimens from different cancers (see
Materials and Methods) showed HER-2 gene amplification or
BiotHER staining, except for two cases of colon cancer. Both cases
were HER-2 gene amplified, BiotHER positive and TAB250
positive. Herceptest was positive in only one of these cases and
negative in the other.
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receiving Trastuzumab for advanced breast cancer
Of the 54 tumour specimens from patients selected for the clinical
outcome analysis, BiotHER was negative (score 0 or 1þ)i n2 7
cases and positive (score 2þ or 3þ) in the remaining 27 cases
(50%). The original tissue specimens of this case series derived
from different laboratories and were probably prepared using
different fixation methods. Seven of these specimens showed
unspecific immunostaining (cytoplasm and/or background stain-
ing and no clear membrane staining) with BiotHER and were thus
ultimately considered negative.
Figure 2 BiotHER immunostaining is restricted to membranes of (A) BT474 cells and of (B) cancer cells in paraffin-embedded tumour samples; (C)n o
background or (D) normal cell staining is observed. (E) BiotHER stains amplified tumour cells (F) (CISH; large gene copy cluster/nucleus), and (E, F arrows)
is negative in normal nonamplified residual cells (two signals/nucleus).
Table 1 Concordance of BiotHER with (a) HercepTest, (b) TAB250
BiotHER score 0–1 2–3 Total No. of specimens
(a)
0–1 85 58 143
2–3 1 20 21
(b)
0–1 109 34 143
2–3 0 21 21
Note: K¼0.45, P o0.01.
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sAt the time of this analysis, 36 patients have progressed and 22
patients have died. The median follow-up for patients who were
still alive at the last follow-up contact was 22 months (range 4–58
months). Overall, the combination of chemotherapy plus Trastu-
zumab produced a 74% RR (95% CI 61–84%). The Kaplan–Meier
estimates of median TTP for the overall population was 11 months
(95% CI 8–14 months, Figure 3). The median overall survival was
not reached (Figure 4). The 2-year survival was 55% (95% CI 39–
71%).
None of the differences seen in the distribution of clinical
characteristics between patients with BiotHER-positive and -
negative tumours approached statistical significance (Table 2).
The RR was significantly higher in BiotHER-positive patients
(89%, 95% CI 72–96%), compared to BiotHER-negative patients
(59%, 95% CI 41–75%) (Table 3).
BiotHER positivity was associated with longer median TTP (19
vs 9 months for patients with BiotHER-positive and -negative
tumours, respectively, P¼0.03) and median OS (not reached vs 23
months for BiotHER-positive and -negative tumours, respectively,
P¼0.04) (Figures 3 and 4).
The effect of BiotHER positivity on RR, TTP and OS was studied
in multivariate analysis models including other variables, which
were found to be significantly associated with the outcomes in the
univariate analysis (data not shown). BiotHER positivity was
independently associated with increased likelihood of tumour
response (Table 4). Of the other potential covariates, only
prior exposure to chemotherapy for metastatic disease was
independently associated with reduced response rate. Survival
analysis showed that BiotHER status was the only independent
predictor for both OS and PFS. BiotHER positivity was associated
with reduced risk of death (HR 0.391, 95% CI 0.152–1.003,
P¼0.05) and tumour progression (HR 0.04, 95% CI 0.213–0.912,
P¼0.03).
DISCUSSION
In the present work, we devised a simple strategy, based on the
biotinylation of Trastuzumab (BiotHER), which allows the use of
the anti-HER-2 humanised Ab for IHC. Thus, BiotHER can be used
as a primary Ab when evaluating the availability of Trastuzumab-
specific binding sites in breast tumour tissue sections. We
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Figure 3 Kaplan–Meier estimates of time to progression (TTP)
according to BiotHER status. The solid line represents patients with
BiotHER-positive tumours and the dashed line patients with BiotHER-
negative tumours.
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Figure 4 Kaplan–Meier estimates of overall survival (OS) according to
BiotHER status. The solid line represents patients with BiotHER-positive
tumours and the dashed line patients with BiotHER-negative tumours.
Table 2 Patients’ demographics according to BiotHER status
BiotHER  BiotHER+
Characteristic N¼27 N¼27
Median age in years (range) 55 (35–75) 50 (36–76)
Median DFS in months (range) 21 (0–134) 24 (0–119)
Median number of metastatic sites (range) 2 (1–4) 2 (1–3)
Patients with single metastatic sites 8 (30%) 11 (41%)
Visceral involvement (liver+lung) 19 (70%) 22 (81%)
Liver involvement 14 (52%) 15 (56%)
Prior chemotherapy for metastatic disease 18 (67%) 23 (85%)
Prior adjuvant/neoadjuvant chemotherapy 15 (56%) 18 (67%)
Prior exposure to antracyclines 18 (67%) 16 (59%)
N¼number; DFS¼disease-free survival from initial diagnosis to metastatic
progression.
Table 3 Response to Trastuzumab-based therapy according to BiotHER
status
Response BiotHER pos. Rate (%)
a BiotHER neg. Rate (%)
CR+PR 24 89
b 16 59
CR 2 7 4 15
PR 22 81 12 44
SD 2 7 9 33
PD 1 4 2 7
aBecause of rounding, the sum of percentages is not always¼100.
bFisher’s exact test
for the difference in the rate of responders (CR+PR), P¼0.03. CR¼complete
remission; PR¼partial remission; SD¼stable disease ; PD¼progressive disease.
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tumours with HER-2 gene amplification. In addition, BiotHER
positivity was a strong predictor of clinical outcome in patients
with advanced breast cancer treated with Trastuzumab and
chemotherapy.
Trastuzumab is a human-murine chimeric mAb, which retains
only the small antigen-binding fragment of the murine 4D5
immunoglobulin (Carter et al, 1992) that specifically recognises the
ECD of HER-2. In clinical trials, to screen patients for enrolment,
immunostaining with 4D5 mAb was used but only in combination
with other Abs (Mass et al, 2001; Slamon et al, 2001; Bookman
et al, 2003) because of concerns that use of 4D5 mAb alone might
underestimate HER-2 detection in formalin-fixed and paraffin-
embedded tissues. The fact that only a subset of FISH-amplified
tumours scored positively by 4D5, as well as by BiotHER in the
present study, may be explained by the shedding of ECD activated
by proteolitic processes. In fact, it has been shown that 22.4% of
breast cancer tissues express only the p95 NH2-truncated form of
HER-2 (Christianson et al, 1998), owing to shedding of ECD. The
possible truncation of HER-2 with loss of ECD prompted us to use
Trastuzumab as the primary Ab in IHC procedures, in order to
select patients whose tumour cells maintain the target epitope. In
addition, 4D5 is not commercially available. HER-2 diagnostic
testing recommendations (Bilous et al, 2003), proposed by
different nations, do not consider 4D5 mAb as an IHC marker
and, to our knowledge, no work has been published on the
correlation between 4D5 immunostaining and HER-2 gene
amplification by FISH analysis in tissue specimens. We decided
upon biotinylation of Trastuzumab to avoid incubation with a
secondary anti-human IgG, which could create problems of
background staining. In addition to reducing the IHC procedure
to a single step (no secondary antibody needed), BiotHER
immunoreaction does not require antigen retrieval. In properly-
fixed tissue samples, we observed that: (i) the IHC reaction with
BiotHER was limited to the plasma membrane of tumour cells; (ii)
no cytoplasmic staining was observed and (iii) normal epithelial or
stromal cells did not react whatsoever. However, in the series of
patients treated with Trastuzumab, we noted suboptimal (i.e.,
cytoplasmic and background) BiotHER staining in seven cases
(three tumours were nonresponsive and four responded to
Trastuzumab treatment) received from external laboratories.
These data confirm the need for optimal tissue processing as a
prerequisite for reliable HER-2 IHC staining (Bilous et al, 2003).
Comparison of the reactivity of BiotHER with that of other
commercially available Abs such as Herceptest and TAB250
demonstrated a low concordance.
Not surprisingly, we observed instead an 87.5% agreement of the
results obtained with BiotHER and mAb 4D5; while 12.5% of IHC
reactivity with mAb 4D5 was not confirmed with BiotHER. The
reason for this minor discrepancy is not clear since Trastuzumab
has a high affinity for the HER-2 ECD (Kd¼5 10
 9 M) although
we cannot exclude that a slight structural variation of the 4D5 Fab
occurred after humanisation. In fact, the crystal structure of mAb
4D5 demonstrates that the complementarity determining region 3,
which determines the antibody–antigen interaction, is composed
of six highly flexible hypervariable loops (Zhang et al, 1999).
When we calculated the specificity of BiotHER reactivity using
the known HER-2 gene status of the tumour as the gold standard,
we observed that none of the unamplified samples were BiotHER-
or 4D5-positive. In addition, differently from Herceptest and
TAB250, all cases positive with BiotHER even those scored as 2þ
showed invariably high level of gene amplification by FISH
analysis (50% sensitivity) and all cases scored as 1þ or 0 were
nonamplified (100% specificity).
The second part of our study evaluated the clinical impact of the
results of BiotHER IHC staining. For this purpose, predictivity of
BiotHER results with respect to RR, TTP and OS was retro-
spectively studied in a series of 54 patients with HER-2 amplified
advanced breast cancer who had received Trastuzumab plus
chemotherapy. Patients whose tumours was BiotHER positive had
superior RR, TTP and OS, compared with patients with BiotHER-
negative tumours. BiotHER positivity was an independent
predictor of clinical outcome in both the overall and the amplified
population. We thus suggest that BiotHER identifies the subset of
patients with HER-2 amplified tumours achieving the highest
benefit from Trastuzumab-based therapy. Obviously, these results
should be interpreted with caution and require prospective
confirmation for two main reasons: (1) the analysis included a
small number of subjects, (2) in the amplified population, the
response rate in patients with BiotHER-negative tumours was 59%,
a rate that does not exclude a possible, even if less pronounced,
benefit from the addition of Trastuzumab to chemotherapy also in
this subset of patients. On the other hand, our findings provide a
possible explanation for the low activity rate of single agent
Trastuzumab in patients selected on the basis of conventional
IHC testing and FISH. As stated before, the ECD of HER-2,
which represents the accessible target for immunotherapy with
Trastuzumab, can be shed (Hayes et al, 2001) and splice variants of
HER-2 with deletion in ECD exons can occur (Christianson et al,
1998; Kwong and Hung, 1998; Molina et al, 2002). Another
explanation to the response of patients with negative BiotHER
immunoreaction is that mechanisms of HER-2 shedding might
change under Trastuzumab therapy and chemotherapy, with less
of the HER-2 protein fragment being released to the serum, which
would make the c-erbB-2-positive tumour cells a better target for
anti-HER-2 antibody treatment (Luftner et al, 1999; Molina et al,
2001).
Both FISH testing and Abs that are directed against the
intracellular domain, such as Herceptest and CB11, or against
undefined ECD epitopes, such as TAB250, do not account
for the possible absence of the Trastuzumab epitope on the cell
surface.
In conclusion, our results suggest that, in patients with breast
cancer and HER-2 gene amplification, the use of BiotHER as
primary Ab in IHC procedures has the potential to further improve
the definition of the target population for Trastuzumab-based
treatment. Furthermore, we provide the first evidence that mAbs
humanised for use in therapy (an increasingly popular approach)
can be used in IHC, simultaneously revealing target availability
and forecasting clinical efficacy.
ACKNOWLEDGEMENTS
This work was supported by grants from the Ministry for
Universities, Instruction and Research (MIUR), Rome, Italy;
MURST (ex 60%), Rome, Italy; the Compagnia di San Paolo/
FIRMS, Torino, Italy. We are grateful to Laura Casorzo, Rosanna
Lupo and Patrizia Gugliotta for technical assistance and Dr Enza
Ferrero (Laboratory of Immunogenetics, Department of Genetics,
Biology and Biochemistry) for suggestions and the careful revision
of the manuscript.
Table 4 Logistic regression analysis of tumour response
Univariate Multivariate
Variable OR 95% CI P OR 95% CI P
BiotHER
positivity
5.500 1.323–22.862 0.04 4.589 1.042–20.207 0.04
Prior
chemotherapy
for metastases
0.176 0.045–0.688 0.01 0.216 0.052–0.906 0.04
OR¼odds ratio; CI¼confidence interval.
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